The EU’s rare disease lottery: treatment depends on your country (euobserver.com)

• EMA approval does not guarantee access in all EU countries.
• Germany provides faster access than Ireland or Malta.
• National pricing and health system differences drive inequality.

"Hundreds of rare disease patients across the EU wait for EMA-approved drugs due to national disparities. Access varies widely between member states like Ireland, Germany, and Malta, driven by differences in health systems, pricing negotiations, and reimbursement policies. The article highlights the personal impact and calls for EU-wide action to ensure equal access."